Sande CJ

Development of a controlled human infection model to study respiratory syncytial virus infection in older adults.Sande CJ
Lancet Healthy Longev, (2022). 3:e370-e371

Implementation strategies for passive respiratory syncytial virus immunisation.Sande CJ
Lancet Infect Dis, (2021). 21:1200-1201

Vaccination against Respiratory Syncytial Virus.Green CA, Drysdale SB, Pollard AJ, Sande CJ
Interdiscip Top Gerontol Geriatr, (2020). 43:182-192

Priorities for developing respiratory syncytial virus vaccines in different target populations.Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ
Sci Transl Med, (2020). 12:

Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects.Sande CJ, Njunge JM, Ngoi JM, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ
Nat Commun, (2019). 10:3291

Airway response to respiratory syncytial virus has incidental antibacterial effects.Sande CJ, Njunge JM, Mwongeli Ngoi J, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ
Nat Commun, (2019). 10:2218

Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya.Nyiro JU, Kiyuka PK, Mutunga MN, Sande CJ, Munywoki PK, Scott JAG, Nokes DJ
Wellcome Open Res, (2019). 4:33

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.Gerretsen HE, Capone S, Vitelli A, Reyes LS, Thompson A, Jones C, Green CA, Pollard AJ, Sande CJ
Vaccine, (2018). 36:6988-6994

Untargeted analysis of the airway proteomes of children with respiratory infections using mass spectrometry based proteomics.Sande CJ, Mutunga M, Muteti J, Berkley JA, Nokes DJ, Njunge J
Sci Rep, (2018). 8:13814

Development of respiratory syncytial virus (RSV) vaccines for infants.Gerretsen HE, Sande CJ
J Infect, (2017). 74 Suppl 1:S143-S146

Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.Nyiro JU, Kombe IK, Sande CJ, Kipkoech J, Kiyuka PK, Onyango CO, Munywoki PK, Kinyanjui TM, Nokes DJ
PLoS One, (2017). 12:e0177803

Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya.Nyiro JU, Sande CJ, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, Nokes DJ
PLoS One, (2016). 11:e0166706

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande CJ, Cane PA, Nokes DJ
Vaccine, (2014). 32:4726-9

Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort.Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ
J Med Virol, (2013). 85:2020-5

Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia.Sande CJ, Mutunga MN, Medley GF, Cane PA, Nokes DJ
J Infect Dis, (2013). 207:489-92

The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease.Ohuma EO, Okiro EA, Ochola R, Sande CJ, Cane PA, Medley GF, Bottomley C, Nokes DJ
Am J Epidemiol, (2012). 176:794-802

Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya.Agoti CN, Mwihuri AG, Sande CJ, Onyango CO, Medley GF, Cane PA, Nokes DJ
J Infect Dis, (2012). 206:1532-41